PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Huaqiang Zhou

Sun Yat-sen University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs1 Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 10, 2026 · JOURNAL ARTICLE

Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations

JAMA

Phase 3 RCT with adequately powered, pre-specified primary endpoint showing clinically significant and statistically robust PFS benefit (HR 0.44, p<.001) in a well-defined population, though OS remains immature and generalizability is limited to China.

Strong EvidenceLi Zhang Lung Cancer Treatments and Mutations Ting Zhou

Reported

Median PFS – combination group34.0 months

Median PFS – monotherapy group15.6 months

Absolute PFS difference18.4 months

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support